Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial

Publication | Open Access

DOI Full Paper Access

140

Citations

References

2011

Year

Aude Fléchon, Damien Pouessel, Céline Ferlay, David Pérol, Philippe Beuzeboc, Gwénaëlle Gravis, Florence Joly, Stéphane Oudard, G. Deplanque, Sylvie Zanetta,

Annals of Oncology

UrologyGenitourinary CancerMedicineP01 TrialPhase Ii StudyNeuroendocrine DifferentiationProstatic DiseaseOncologyRadiation Oncology